Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis

Published:2022-06 Issue:3 Volume:7 Page:100465
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Siciliano M.A.,Caridà G.,Ciliberto D.,d’Apolito M.,Pelaia C.,Caracciolo D.,Riillo C.,Correale P.,Galvano A.,Russo A.,Barbieri V.,Tassone P.,Tagliaferri P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference48 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

5. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial;Lung Cancer;2024-07

2. Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors;Expert Opinion on Pharmacotherapy;2024-05-23

3. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis;Clinical and Translational Oncology;2024-04-16

4. Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer;Thoracic Cancer;2024-04-11

5. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer;Future Oncology;2024-04